Clinical Trial Update: 177Lu-PSMA-R2 in Patients With PSMA Positive Progressive, Metastatic, Castration Resistant Prostate Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial of 177Lu-PSMA-R2 in PSMA-positive metastatic castration-resistant prostate cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• 177Lu-PSMA-R2 (Lutetium-177 PSMA-R2)

Snippet

Sponsor: Advanced Accelerator Applications | Conditions: Prostatic Neoplasm | Phase 1 | Status: TERMINATED